Get the latest Science News and Discoveries

Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen - EurekAlert


A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona. The results suggest that antibody responses contributed to the effectiveness of dose-sparing mpox vaccine regimens used during the 2022 U.S. outbreak. 

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of Lower dose

Lower dose

Photo of mpox vaccine

mpox vaccine

Photo of standard regimen

standard regimen

Related news:

News photo

Comment rendre l'air de New Dehli plus propre? - EurekAlert

News photo

It's not a match! Skill mismatch after job loss can have great impact on career - EurekAlert

News photo

Recent progress of narrowband perovskite photodetectors: fundamental physics and strategies - EurekAlert